Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables growth accelerates

Q1 FY2026 accounts receivables of $267K rose 281.4% year over year, ahead of the -65.5% change in trailing-twelve-month accounts receivables. Sequentially, it fell 87.4% from the prior quarter. Over 3 fiscal years it compounded at -17.4% a year.

Context

  • Accounts receivables amounted to 0.7% of revenue in FY2025, down 101.0 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +281.4% holds above the trailing-twelve-month pace of -65.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$267K-87.4% QoQ
Last fiscal yearDec 2025
$268K-99.7% YoY
LTMMar 2026
$465K-65.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+281.4%——
1 year-99.7%——
3-year CAGR-17.4%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
268K USD
Year-over-year change
-99.7%
4-year CAGR
-56.2%

Accounts Receivables vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's LTM Mar 2026 accounts receivables of $465K is the 6th largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -65.5% is the 5th highest of 7, against a peer median of +31.4%.
  • Accounts receivables amounts to 1.3% of revenue for VYGR, versus a peer median of 21.8%.
VYGR Competitors Peer median
Accounts Receivables for VYGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$32.8M +4000.1%+39.1%47.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M +6.6%—29.4%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$12.33M +56.3%+89.9%5.7%
PYXSPyxis Oncology, Inc.LTM Mar 2026$3M -137.5%—21.6%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$1.26M -98.3%—21.9%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$465K -65.5%-17.4%1.3%
HUMAHumacyte, Inc.LTM Mar 2026$54K +117.5%—2.7%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$0 ———
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 ———
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding VYGR) $0+31.4%+64.5%21.8%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.2M)(46.41M)132.33M(65M)(119.72M)
Depreciation & Amortization5.17M6.19M4.44M4.73M4.06M
Deferred Income Tax00000
Stock-Based Compensation11.32M9.34M11.15M14.79M14.79M
Change in Working Capital3.29M20.47M(66.56M)34.86M(28.76M)
Accounts Receivables7.28M475K(83.23M)81.31M268K
Inventory00000
Accounts Payables(60K)1.99M(962K)2.39M1.02M
Other Working Capital(3.93M)18M17.64M(48.84M)(30.05M)
Other Non-Cash Items(2.11M)(2.11M)(3.45M)(4.68M)(2.83M)
Operating Cash Flow(53.53M)(12.51M)77.92M(15.31M)(132.47M)
Capital Expenditures(1.61M)(2.49M)(3.26M)(3.52M)(2.6M)
Acquisitions (Net)00138.39M00
Purchases of Investments(15.12M)(54.85M)(223.97M)(465.69M)(133.93M)
Sales of Investments82.63M50M85.58M374.35M261.97M
Other Investing Activities00(138.39M)00
Investing Cash Flow65.91M(7.34M)(141.64M)(94.86M)125.45M
Debt Repayment00000
Common Stock Issued612K1.11M33.65M114.02M816K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow612K1.11M33.65M114.02M816K
Effect of Forex Changes0264K000
Net Change in Cash12.99M(18.47M)(30.08M)3.85M(6.21M)
Free Cash Flow(55.13M)(15M)74.66M(18.83M)(135.06M)

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.